Bio-Thera Launches Adalimumab In China
Qletli Biosimilar Is First Chinese Humira Rival
Bio-Thera Solutions has launched its first product in China, with its Qletli adalimumab biosimilar representing the first Humira rival to be approved under the country’s biosimilars pathway and just the second biosimilar approved overall.
You may also be interested in...
Bio-Thera Solutions has secured only the second biosimilar approval ever from China’s NMPA, and the country’s first biosimilar approval for a rival to Humira (adalimumab).
Approval of China's first rituximab biosimilar under new pathway gives developers much-needed boost and an opening to the international market for made-in-China biosimilars helped by favorable regulatory policy changes at home.
Pfizer’s Greenstone subsidiary has struck a deal with digital healthcare clinic Roman to offer members access to its authorized generic version of Viagra.